[1] Guzzo C. Recent advances in the treatment of psoriasis. Dermatol Clin, 1997,15:59-68. [2] Ryu DD, Nam DH. Recent progress in biomolecular engineering. Biotechnol Prog,2000, 6:2-16. [3] Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol, 2002,46:1-23. [4] Knappik A, Ge L, Honegger A, et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol, 2000,296:57-86. [5] Nickoloff B J, Wrone-Smith T. Injection of pre-psoriatic skin with CD4 + T cells induces psoriasis. Am J Pathol, 1999,155:145-158. [6] Lonberg N, Huszar D. Human antibodies from transgenic mice. Int Rev Immunol,1995,13:65-93. [7] Bachelez H, Flageul B, Dubertret L, et al.Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. J Autoimmun, 1998,11:53-62. [8] Owen CM, Harrison PV. Successful treatment of severe psoriasis with basiiliximab,an interleukin-2 receptor monoclonal antibody. Clin Exp Dermatol, 2000,25:195-197. [9] Magilavy D, Mant T, Norman P, et al. Pharmacodynamic effects of LFA3TIP(Amevive)in patients with chronic plaque psoriasis (CPP):selective modulation of CD45RO+lymphocytes. J Invest Dermatol, 1999,112:609(abstr). [10] Bagel J, Garland WT, Breneman D, et al.Administration of DAB389 IL-2 to patients with recalcitrant psoriasis:a double-blind,phase Ⅱ multicenter trial. J Am Acad Dermatol, 1998,38:938-944. [11] Mrowietz U, Zhu K J, Christophers E. Treatment of severe psoriasis with anti-CD25 monoclonal antibodies. Arch Dermatol,2000,136:675-676. [12] Krueger JG, Walters IB, Miyazawa M, et al.Successful in vivo blockade of CD25 (highaffinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol, 2000,43:448-458. [13] Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNFalpha) monoclonal antibody dramatically decreases the clinical avtivity of psoriasis lesions. J Am Acad Dermatol, 2000,42(5 Pt 1):829-830. [14] Wohlrab J, Fischer M, Taube KM, et al.Treatment of recalcitrant psoriasis with daclizumab. Br J Dermatol, 2001,144:209-210. [15] Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med, 1998,338:161-165. [16] Gottlieb A, Krueger JG, Bright R, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol, 2000,42:428-435. [17] Ogilvie AL, Antoni C, Dechant C, et al.Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol,2001,144:587-589. [18] Hong K, Chu A, Ludviksson BR, et al. IL12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol,1999,162:7480-1791. [19] Montero E, Falcon L, Morera Y, et al. CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior tl MAb a possible new approach to treat this disease. Autoimmunity, 1999,29:155-156. [20] Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximabnonotherapy for plaque-type psoriasis:a randomised trial. Lancet, 2001,357 (9271):1842-1847. [21] Kirby B, Marsland AM, Carmichael AJ, et al. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol, 2001,26:27-29. [22] Krueger JG, Walters IB, Miyazawa M, et al.Successful in vivo blockade of CD25 (highaffinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol, 2000,43:448-458. [23] Nickoloff B J, Mitra RS, Varani J, et al.Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol, 1994,144:820-828. [24] Kirby B, Griffiths CE. Psoriasis:the future.Br J Dermatol, 2001,144 (Suppl 58):37-43. [25] 颜文飞,郑敏,孙国均.角质形成细胞生长因子及神经细胞生长因子在银屑病患者皮损中的表达.中华皮肤科杂志,2002,35:94-96. [26] 陈积愫,郑敏.寻常型银屑病患者血管内皮生长因子及单核细胞趋化因子-1表达的研究.中华皮肤科杂志,2002,35:111-113. [27] 周利平,杨木兰,江涛,等.银屑病患者Fas及Bcl-2的表达及中药的作用.中华皮肤科杂志,2002,35:146-147. [28] Wu Shao-xi. New progress in treatment of psoriasis. Chinese Journal of Integrated Traditional and Western Medicine, 2002,8:253-254. |